MARCHF1 and ovarian carcinoma: Our result was consistent with a study that showed that the MARCH1 knockdown results in NF‐κB and β‐catenin inhibition in ovarian cancer.13 Previous studies have demonstrated that MARCH1 was a negative regulator of INSR signalling in various cell types, including hepatocytes and white adipocytes.